SCHEMBL952317

SCHEMBL952317

CC(=O)Nc1cc(-c2nc(-c3ccccc3)c(C(=O)O)s2)cc(C)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 5/20 0.53
DBF4 Q9UBU7 5/20 0.53
ALDH1A1 P00352 4/20 0.53
KDM4E B2RXH2 2/20 0.53
MAPT P10636 1/20 0.53
ADORA1 P30542 3/20 0.48
ADORA3 P0DMS8 3/20 0.48
ADORA2B P29275 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
ADORA2A P29274 2/20 0.45
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
CDK2 P24941 2/20 0.44
CHUK O15111 1/20 0.44
PRKD3 O94806 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL955820 0.91 CDC7 (0.55) CDC7DBF4ALDH1A1KDM4EMAPT
SCHEMBL953320 0.87 MEN1 (0.65) CDC7DBF4ALDH1A1KDM4EADORA1
SCHEMBL954260 0.84 CDC7 (0.60) CDC7DBF4ALDH1A1KDM4EMAPT
SCHEMBL952202 0.78 MAPT (0.45) ALDH1A1KDM4EMAPTADORA1ADORA3
SCHEMBL974859 0.76 CDC7 (0.84) CDC7DBF4ALDH1A1KDM4EMAPT
SCHEMBL953055 0.75 CDC7 (0.61) CDC7DBF4ALDH1A1KDM4EMAPT
SCHEMBL15064944 0.74 KMT2A (0.70) ALDH1A1KDM4EMAPTADORA1ADORA3
SCHEMBL957562 0.73 CDC7 (0.71) CDC7DBF4ALDH1A1KDM4EADORA1
SCHEMBL15716809 0.72 CDC7 (0.63) CDC7DBF4ALDH1A1KDM4EMAPT
SCHEMBL3781136 0.72 ADORA3 (0.43) ALDH1A1KDM4EMAPTADORA1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
CN-102395585-A Heteroaryls and their use as pi3k inhibitors MILLENNIUM PHARM INC 2012-03-28 CN disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 CDC7 601/4885DBF4 3288/4885ALDH1A1 1687/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 CDC7 1063/4885DBF4 3779/4885ALDH1A1 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.